Citing transparency, PBM startup Capital Rx introduces novel pricing model
As retail prescription drug spending continues to grow, the push toward price transparency has been hindered by some industry players and helped by others. With its announcement of a model meant to eliminate arbitrary prescription drug pricing and let patients and employers know what they’ll be paying for medication, Capital Rx clearly wants a place in the latter group.
